Evidence map›Paper›PMID 42344699›Full record

ArticleFrontiers in oncology2026

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Darren Hargrave, Lynley V Marshall, Nicolas André, Julie Krystal, Brian H Ladle, Karen A Robbins, Stephan Hois, Jon Armstrong, Sarah Donegan

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Darren HargraveUniversity College London Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, London, United Kingdom.
Lynley V MarshallPediatric and Adolescent Oncology Drug Development Unit, Oak Centre for Children and Young People, The Royal Marsden Hospital and Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Nicolas AndréPediatric Hematology and Oncology Department, Hôpital pour Enfant de La Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), and Reverse Molecular Pharmacology in Pediatric Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, CNRS, INSERM, Marseille, France.
Julie KrystalZucker Hofstra School of Medicine, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park, NY, United States.
Brian H LadleSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Karen A RobbinsGlobal Patient Safety, Oncology, AstraZeneca, Gaithersburg, MD, United States.
Stephan HoisLate-stage Development Oncology R&D, AstraZeneca, Gaithersburg, MD, United States.
Jon ArmstrongOncology Biometrics, AstraZeneca, Cambridge, United Kingdom.
Sarah DoneganOncology R&D, AstraZeneca, Gaithersburg, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2026.1680081.].

Indexed as

antitumor activitybiomarker analysiscombination therapycytotoxic T-lymphocyte associated protein 4 inhibitorpharmacokineticsprogrammed death ligand 1 inhibitorsolid tumors

Identifiers

PMID42344699
PMCPMC13288219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.